Asemisynthetic carbohydrate-lipid vaccine that protects against S. pneumoniae in mice

Nature Chemical Biology

Volumn 10, Issue 11, 2014, Pages 950-956

  Cavallari, Marco ^a,e   Stallforth, Pierre ^b,f   Kalinichenko, Artem ^a   Rathwell, Dominea C K ^b   Gronewold, Thomas M A ^c   Adibekian, Alexander ^b,g   Mori, Lucia ^a,d   Landmann, Regine ^a   Seeberger, Peter H ^b   De Libero, Gennaro ^a,d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b MAX PLANCK INSTITUTE OF COLLOIDS AND INTERFACES   (Germany)

^c SAW Instruments GmbH   (Germany)

^d AGENCY FOR SCIENCE   (Singapore)

^e WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^f HANS KNÖLL INSTITUTE   (Germany)

^g UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP A ANTIGEN; CD1D ANTIGEN; GALACTOSYLCERAMIDE; IMMUNOGLOBULIN G ANTIBODY; LIPID; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE; CARBOHYDRATE; MONOCLONAL ANTIBODY; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; GERMINAL CENTER; HELPER CELL; MEMORY CELL; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PHENOTYPE; PLASMABLAST; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; VACCINATION; ANIMAL; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; BAGG ALBINO MOUSE; C57BL MOUSE; CELL LINE; CHEMISTRY; CYTOLOGY; HL 60 CELL LINE; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; KINETICS; KNOCKOUT MOUSE; METABOLISM; PASSIVE IMMUNIZATION; SYNTHESIS; TIME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD1D; B-LYMPHOCYTES; CARBOHYDRATES; CELL LINE; GERMINAL CENTER; HL-60 CELLS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOLOGIC MEMORY; KINETICS; LIPIDS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NATURAL KILLER T-CELLS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS; VACCINES, SYNTHETIC;

EID: 84924285509     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1650     Document Type: Article

References (50)

1. Chang, Q., Zhong, Z., Lees, A., Pekna, M. & Pirofski, L. Structure-function relationships for human antibodies to pneumococcal capsular polysaccharide from transgenic mice with human immunoglobulin Loci. Infect. Immun. 70, 4977-4986 (2002).
2. Yarema, K. J. & Bertozzi, C. R. Chemical approaches to glycobiology and emerging carbohydrate-based therapeutic agents. Curr. Opin. Chem. Biol. 2, 49-61 (1998).
3. Danishefsky, S. J. & Allen, J. R. From the laboratory to the clinic: a retrospective on fully synthetic carbohydrate-based anticancer vaccines frequently used abbreviations are listed in the appendix. Angew. Chem. Int. Edn Engl. 39, 836-863 (2000).
4. Schofield, L., Hewitt, M. C., Evans, K., Siomos, M. A. & Seeberger, P. H. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 418, 785-789 (2002).
5. Verez-Bencomo, V. et al. A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 305, 522-525 (2004).
6. Slovin, S. F., Keding, S. J. & Ragupathi, G. Carbohydrate vaccines as immunotherapy for cancer. Immunol. Cell Biol. 83, 418-428 (2005).
7. Vliegenthart, J. F. Carbohydrate based vaccines. FEBS Lett. 580, 2945-2950 (2006).
8. Ingale, S., Wolfert, M. A., Gaekwad, J., Buskas, T. & Boons, G. J. Robust immune responses elicited by a fully synthetic three-component vaccine. Nat. Chem. Biol. 3, 663-667 (2007).
9. Hecht, M.-L., Stallforth, P., Silva, D. V., Adibekian, A. & Seeberger, P. H. Recent advances in carbohydrate-based vaccines. Curr. Opin. Chem. Biol. 13, 354-359 (2009).
10. Phalipon, A. et al. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection. J. Immunol. 182, 2241-2247 (2009).
11. Astronomo, R. D. & Burton, D. R. Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat. Rev. Drug Discov. 9, 308-324 (2010).
12. Goldblatt, D. Recent developments in bacterial conjugate vaccines. J. Med. Microbiol. 47, 563-567 (1998).
13. Colino, J. et al. Parameters underlying distinct T cell-dependent polysaccharide-specific IgG responses to an intact Gram-positive bacterium versus a soluble conjugate vaccine. J. Immunol. 183, 1551-1559 (2009).
14. Bogaert, D., De Groot, R. & Hermans, P. W. M. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect. Dis. 4, 144-154 (2004).
15. Miller, E., Andrews, N. J., Waight, P. A., Slack, M. P. & George, R. C. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect. Dis. 11, 760-768 (2011).
16. Weinberger, D. M., Malley, R. & Lipsitch, M. Serotype replacement in disease after pneumococcal vaccination. Lancet 378, 1962-1973 (2011).
17. Johnson, D. R., D'Onise, K., Holland, R. A., Raupach, J. C. A. & Koehler, A. P. Pneumococcal disease in South Australia: vaccine success but no time for complacency. Vaccine 30, 2206-2211 (2012).
18. Alexandre, C. et al. Rebound in the incidence of pneumococcal meningitis in northern France: effect of serotype replacement. Acta Paediatr. 99, 1686-1690 (2010).
19. Tyo, K. R. et al. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Vaccine 29, 6686-6694 (2011).
20. Brandau, D. T., Jones, L. S., Wiethoff, C. M., Rexroad, J. & Middaugh, C. R. Thermal stability of vaccines. J. Pharm. Sci. 92, 218-231 (2003).
21. van Gils, E. J. M. et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. J. Am. Med. Assoc. 302, 159-167 (2009).
22. Russell, F. M. et al. Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster. Clin. Vaccine Immunol. 17, 1970-1976 (2010).
23. Kawano, T. et al. CD1d-restricted and TCR-mediated activation of vα14 NKT cells by glycosylceramides. Science 278, 1626-1629 (1997).
24. Gonzalez-Aseguinolaza, G. et al. Natural killer T cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 195, 617-624 (2002).
25. Cerundolo, V., Silk, J. D., Masri, S. H. & Salio, M. Harnessing invariant NKT cells in vaccination strategies. Nat. Rev. Immunol. 9, 28-38 (2009).
26. + T cell differentiation during viral infection. PLoS ONE 7, e37991 (2012).
27. Richter, J. et al. Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood 121, 423-430 (2013).
28. Nagato, K. et al. Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-galactosylceramide-pulsed antigen presenting cells. J. Clin. Immunol. 32, 1071-1081 (2012).
29. Zhou, X.-T. et al. Synthesis and NKT cell stimulating properties of fluorophore- and biotin-appended 6"-amino-6"-deoxy-galactosylceramides. Org. Lett. 4, 1267-1270 (2002).
30. Kohn, J. & Wilchek, M. Mechanism of activation of Sepharose and Sephadex by cyanogen bromide. Enzyme Microb. Technol. 4, 161-163 (1982).
31. Coughlin, R. T. et al. Characterization of pneumococcal specific antibodies in healthy unvaccinated adults. Vaccine 16, 1761-1767 (1998).
32. Saeland, E. et al. Central role of complement in passive protection by human IgG1 and IgG2 anti-pneumococcal antibodies in mice. J. Immunol. 170, 6158-6164 (2003).
33. Carnaud, C. et al. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163, 4647-4650 (1999).
34. Fujii, S., Shimizu, K., Smith, C., Bonifaz, L. & Steinman, R. M. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198, 267-279 (2003).
35. Tomayko, M. M., Steinel, N. C., Anderson, S. M. & Shlomchik, M. J. Cutting edge: Hierarchy of maturity of murine memory B cell subsets. J. Immunol. 185, 7146-7150 (2010).
36. Yamashita, Y. et al. CD73 expression and fyn-dependent signaling on murine lymphocytes. Eur. J. Immunol. 28, 2981-2990 (1998).
37. Anderson, S. M., Tomayko, M. M., Ahuja, A., Haberman, A. M. & Shlomchik, M. J. New markers for murine memory B cells that define mutated and unmutated subsets. J. Exp. Med. 204, 2103-2114 (2007).
38. Chang, P. P. et al. Identification of Bcl-6-dependent follicular helper NKT cells that provide cognate help for B cell responses. Nat. Immunol. 13, 35-43 (2012).
39. Bendelac, A., Savage, P. B. & Teyton, L. The biology of NKT cells. Annu. Rev. Immunol. 25, 297-336 (2007).
40. Fattom, A. et al. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. Vaccine 17, 126-133 (1999).
41. Avci, F. Y., Li, X., Tsuji, M. & Kasper, D. L. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat. Med. 17, 1602-1609 (2011).
42. King, I. L. et al. Invariant natural killer T cells direct B cell responses to cognate lipid antigen in an IL-21-dependent manner. Nat. Immunol. 13, 44-50 (2012).
43. Dellabona, P., Abrignani, S. & Casorati, G. iNKT-cell help to B cells: a cooperative job between innate and adaptive immune responses. Eur. J. Immunol. 44, 2230-2237 (2014).
44. + T cell help. J. Immunol. 188, 3217-3222 (2012).
45. Bai, L. et al. Natural killer T (NKT)-B-cell interactions promote prolonged antibody responses and long-term memory to pneumococcal capsular polysaccharides. Proc. Natl. Acad. Sci. USA 110, 16097-16102 (2013).
46. Brossay, L. et al. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J. Exp. Med. 188, 1521-1528 (1998).
47. Franchini, L. et al. Synthesis and evaluation of human T cell stimulating activity of an alpha-sulfatide analogue. Bioorg. Med. Chem. 15, 5529-5536 (2007).
48. Kyriakakis, E. et al. Invariant natural killer T cells: linking inflammation and neovascularization in human atherosclerosis. Eur. J. Immunol. 40, 3268-3279 (2010).
49. Smiley, S. T., Kaplan, M. H. & Grusby, M. J. Immunoglobulin E production in the absence of interleukin-4-secreting CD1-dependent cells. Science (New York, N. Y.) 275, 977-979 (1997).
50. Facciotti, F. et al. Fine tuning by human CD1e of lipid-specific immune responses. Proc. Natl. Acad. Sci. USA 108, 14228-14233 (2011).